Pranshu Mohindra, MD, MBBS

Education

• 1997 – 2003: M.B.B.S, Dr D Y Patil Medical College, University of Mumbai, India Date of Degree: 12/2003
• 2004 – 2007: M.D., Tata Memorial Hospital, University of Mumbai, India Date of Degree: 02/2008
  MD Dissertation: Low dose Total Body Irradiation in cases of Low Grade Non-Hodgkin’s Lymphoma: Response evaluation & Immunological-Radiobiological assessment of mechanism.
  Advisor: Dr. Mary Ann Muckaden

Post Graduate Education and Training

• 2002 – 2003: Internship: Dr D Y Patil Medical College, University of Mumbai, India
• 2004 – 2007: Residency: Radiation Oncology, Tata Memorial Hospital, University of Mumbai, India
• 2006 – 2007: Professional Diploma in Clinical Research: Catalyst Clinical Services Pvt. Ltd., India (Correspondence Course)
• 2007 – 2008: Senior Residency (Fellow): Radiation Oncology Tata Memorial Hospital, India
• 2009 – 2009: Global Academic Research Associate (Post-doctoral fellow): University of Texas MD. Anderson Cancer Center, Houston, Texas, USA,Supervisor: Dr. S. Krishnan
• 2009 – 2010: Clinical Fellow: Radiation Oncology (Head and Neck Cancer)Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Canada, Program Director: Dr. Charles Catton
• 2010 – 2014: Residency: Radiation Oncology University of Wisconsin Hospital and Clinics, Madison, WI, Program Director: Dr. Kristin A Bradley

Certifications

• 2003 M.B.B.S, University of Mumbai, India
• 2008 M.D. (Radiotherapy), University of Mumbai, India
• 2015 American Board of Radiology- Radiation Oncology

Dr. Mohindra’s prior training experience includes two radiation oncology residencies (Tata Memorial Centre, Mumbai and University of Wisconsin, Madison), Head-Neck cancer clinical fellowship (Princess Margaret Hospital, University of Toronto) and a post-doctoral Global Academic Research Associate at the U. T. MD Anderson Cancer Center; Houston. He has received several academic excellence, research and travel awards during his residency including the 2014 Radiological Society of North America (RSNA) Roentgen Resident/Fellow Award for outstanding radiologic research and the 2014 American Society for Radiation Oncology (ASTRO) Resident Digital Poster Discussion Award in the Biology category. He also served as the Chief resident, Radiation Oncology, University of Wisconsin, Madison, for the year 2013-14.

Dr. Mohindra joined the Department of Radiation Oncology at the University of Maryland School of Medicine, Baltimore in July 2014 as an assistant professor in a clinician-scientist role. His primary area of clinical and research interest is in thoracic/lung, gynecological and hemato-lymphoid malignancies. Dr. Mohinda played a key role in the initiation of the department’s MRI-guided brachytheapy program for women with cervical cancer. He has helped establish UMMC as a referral center for complex high dose rate (HDR) tandem-ring brachytherapy and interstitial brachytherapy for gynecological cancers. Dr. Mohindra is amongst the select providers in the entire Maryland-DC region who has the expertise in performing these brachytherapy procedures. He is currently working on expanding the use of modern technologies like proton beam therapy for the management of thoracic/lung, gynecological and hemato-lymphoid malignancies.

While continuing to build novel clinical programs and providing expert radiation oncology service, one of his key goals is to represent UMSOM nationally through cutting-edge research. His research efforts include evaluating treatment outcomes through institutional and population-based databases, development of early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques including proton beam therapy. He has active involvement in multi-disciplinary collaborative research endeavors including prospective clinical protocols with special emphasis on early phase clinical trials evaluating both radiation sensitizers and radiation toxicity mitigators or evaluation of modern radiation techniques. He is the national PI of two NCI-sponsored phase-I clinical trials; one evaluating VX-970, a novel DNA repair pathway inhibitor with whole brain radiotherapy (WBRT) in patients with brain metastases from NSCLC (CIRB and CTEP approved, NCT02589522, career development project team award) and another evaluating the combination of oral 5-iodo-2-pyrimidinone-2-deoxyribose (IPdR) with WBRT in brain metastases (CIRB and CTEP approved, NCT02993146). He is the Radiation Oncology Co-chair for the Alliance for Clinical Trials in Oncology A041501A study: Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL and Alliance Champion for the NRG-sponsored national study: LU002 Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial.

Dr. Mohindra represents UMGCCC as the nominated member to the Board of Directors for the Alliance for Clinical Trials in Oncology which comprises nearly 10,000 cancer specialists at hospitals, medical centers, and community clinics across the United States and Canada. He holds committee appointments within Alliance (Radiation Oncology, Respiratory, Symptom Intervention and Cancer in the Older Adults) and American Society for Radiation Oncology (Workforce and Research Grants Evaluation Subcommittee). He was recently also appointed as member of the Advanced Radiation Technology Committee, International Association for the Study of Lung Cancer (IASLC). He is an appointed member of the ACR Radiation Oncology In-Training (TXIT^TM) Exam committee (Thoracic: 2015-2016 and Gynecology, Lymphoma: 2016) developing examination questions for residents in radiation oncology. Since 2017, he took over as the section chair for Thoracic section of the examination.

Within the Department of Radiation Oncology, UMB, Dr. Mohindra is appointed as Director of Research Internships and oversee the activities of all research-related internships that span more than 30 days. Through 2017 and 2018, this program has awarded $20,000 in awards to five UMSOM medical students for summer fellowships, two medical student research scholarship award and one medical student graduation research award. He has personally mentored medical students and residents on research projects that have led to national awards: Applied Radiation Oncology Clinical Case Contest Winner (Stephanie Rice, MS-4, Univ. Wisconsin, 2014), Medical Student Award for 2017 Alpha Omega Alpha Carolyn Kuckein Fellowship Competition (Jiun Yiing Hu, MS-1, UMSOM, 2017) and Radiation Oncology Institute Excellence Award for a research manuscript (Melissa Vyfhuis, Chief Resident Radiation Oncology, UMSOM, 2017).  He is also the Lead, Scope of Practice, Policy and Procedure Management Workgroup of Quality and Safety Review Council. In this role, he will oversee development of SOPs for various departmental clinical activities and establish uniform procedures system-wise.

thoracic/lung cancers, gynecological malignancies, hemato-lymphoid malignancies, intensity modulated proton therapy (IMPT)/pencil beam scanning (PBS) proton therapy, intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), Image-guided Brachytherapy.

CONTRIBUTIONS TO SCIENCE

Contributions in Thoracic-Oncology:

1. Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, Cannon GM.Dose Limiting Toxicity Following Hypofractionated Dose-Escalated Radiotherapy in Non-Small Cell Lung Cancer. JCO 2013 Oct. 21. PMID: 24145340
2. Murigi FN, Mohindra P, Hung C, Salimi S, Goetz W, Pavlovic R, Jackson IL, Vujaskovic Z. Dose Optimization Study of AEOL 10150 as a Mitigator of Radiation-Induced Lung Injury in CBA/J Mice. Radiat Res. 2015 Oct;184(4):422-32. Epub 2015 Sep 28. PMID: 26414508
3. Mohindra P, Barrow K, Kieta KM, Parker J, De Faria E, Taylor-Howell C, Dobbin T, Gibbs A, Farese AM, MacVittie TJ. Use of Computed Tomography (CT) scan to Assess Efficacy of Mitigators of Radiation-induced Lung Injury (RILI): A Rhesus Macaque Whole Thoracic Lung Irradiation (WTLI) Model. IJROBP, 2015:93(3), Supplement, Page E512. Abstract only.
4. de Faria EB, Barrow KR, Ruehle BT, Parker JT, Swartz E, Taylor-Howell C, Kieta KM, Lees CJ, Sleeper MM, Dobbin T, Baron AD, Mohindra P, MacVittie TJ. The Evolving Mcart Multimodal Imaging Core: Establishing a Protocol for Computed Tomography and Echocardiography in the Rhesus Macaque to Perform Longitudinal Analysis of Radiation-Induced Organ Injury. Health Phys. 2015 Nov;109(5):479-92. PMID: 26425907
5. Lam VK, Bentzen SM, Mohindra P, Nichols EM, Bhooshan N, Vyfhuis M, Scilla KA, Feigenberg SJ, Edelman MJ, Feliciano JL. Obesity is associated with long-term improved survival in definitively treated locally advanced non-small cell lung cancer (NSCLC). Lung Cancer. 2017 Feb;104:52-57. PMID: 28213000.
6. Diwanji TP, Mohindra P, Vyfhuis M, Snider JW, Kalavagunta C, Mossahebi S, Yu J, Feigenberg S, Badiyan S. Advances in Radiotherapy Techniques and Delivery for NSCLC: Benefits of IMRT, Proton Therapy, and SBRT. Transl Lung Cancer Res. 2017 Apr;6(2):131-147. PMID: 28529896.
7. Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. Oncologist. 2017 Jun;22(6):737-742. PMID: 28533476.
8. Vyfhuis MA, Bhooshan N, Burrows WM, Turner M, Suntharalingam M, Donahue J, Nichols EM, Feliciano J, Bentzen S, Badiyan S, Carr, SR, Friedberg J, Simone CB, Edelman MJ, Feigenberg S, Mohindra P. Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer. Adv Radiat Oncol (2017). 2017 Sept;2(3):259-269.
9. Vyfhuis M AL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano JF, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB, Feigenberg SJ, Mohindra P. Clinical outcomes of black vs. non-black patients with locally advanced non–small cell lung cancer. Lung Cancer. 2017; 114:44-49, DOI: 10.1016/j.lungcan.2017.10.016.
10. Vyfhuis M AL, Burrows WM, Bhooshan N, Suntharalingam M, Donahue J, Feliciano JF, Badiyan S, Nichols EM, Edelman MJ, Carr SR, Friedberg J, Henry G, Stewart S, Sachdeva A, Pickering EM, Simone CB, Feigenberg SJ, Mohindra P. Implications of Pathological Complete Response (pCR) Beyond Mediastinal Nodal Clearance with High-dose Neoadjuvant Chemoradiotherapy (CRT) in Locally Advanced, Non-Small Cell Lung Cancer (LA-NSCLC). Article in press. IJROBP. DOI: 10.1016/j.ijrobp.2018.02.003
11. Vyfhuis MAL, Rice S, Remick J, Mossahebi S, Badiyan S, Mohindra P, Simone CB. Reirradiation for locoregionally recurrent non-small cell lung cancer. Accepted. J Thorac Dis. 2018.
12. Molitoris JK, Diwanji T, Snider JW, Mossahebi S, Samanta S, Badiyan SN, Simone CB, Mohindra P. Advances in the Use of Motion Management and Image Guidance in Radiation Therapy Treatment for Lung Cancer. Accepted. J Thorac Dis. 2018.

Contributions in Gynecology-Oncology: 

1. Mishra S, Laskar S, Muckaden MA, Mohindra P, Shrivastava SK, Dinshaw KA. Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix. Journal of Cancer Research & Therapeutics. 2005 Oct; 1(4): 208-212. PMID: 17998655.
2. Mohindra P, Kruser TJ, Gondi V, Thomas SR, McHaffie DR, Bradley KA. Papillary serous and clear cell adenocarcinoma of the uterus: A 10-year single-institution experience. IJROBP, 2011;81(2):Supplement, Pages S471-S472. Poster Presentation– ASTRO 53^rd Annual Meeting 2011; Miami.
3. Mohindra P, Bentzen SM, Scartoni D, Giacomelli I, Rao G, Roque DM, Hanna N, Nichols EM. Adjuvant Therapy for Locoregionally Advanced Endometrioid Adenocarcinoma (EA): Upfront Chemotherapy (UC) or Upfront Radiotherapy (UR)? IJROBP, 2016:96(2), Supplement, Page E289-290.Abstract only.
4. Mohindra P, Bentzen SM, Giacomelli I, Scartoni D, Roque DM, Rao G, Hanna N, Nichols EM. Adjuvant Whole Pelvic Radiation Therapy (WPRT) for Endometrioid Adenocarcinoma (EA): 45 Gy or 50/50.4 Gy? IJROBP, 2016:96(2), Supplement, Page E300. Abstract only.
5. Nichols EM, Bentzen SM, Scartoni D, Giacomelli I, Rao G, Roque DM, Hanna N,Mohindra P. Positive impact of radiation therapy in the management of uterine carcinosarcoma. IJROBP, 2016:96(2), Supplement, Page S49. Abstract only.
6. Cohen J, Harper A, Nichols E M, Rao GG, Mohindra P, Roque DM. Barriers to Timely Completion of Radiation Therapy in Patients with Cervical Cancer in an Urban Tertiary Care Center. Cureus 2017 Sep; 9(9): e1681. doi:10.7759/cureus.1681
7. Molitoris JK, Diwanji T, Samanta S, Lamichhane N, Chhabra A, Roque D, Rao G, Amin P, Nichols E, Mohindra P. Improving Outcomes through Immune System Modulation in the Treatment of Gynecological Malignancies. Reproductive Immunol Open Acc, 2017;2:34.
8. Fowler KG, Mohindra P, Kim A, Gomez-Lobo V Foley Catheter As Vaginal Stent In A Toddler With Vaginal Rhabdomyosarcoma. J Pediatr Adolesc Gynecol. 2017 Dec 9. doi: 10.1016/j.jpag.2017.12.003. [Epub ahead of print]

Contributions in Head-Neck Oncology:  

1. Mohindra P, Urban E, Pagan JD, Geye HM, Patel VB, Bayliss RA, Bender ET, Harari PM. Selective omission of level V nodal coverage for patients with oropharynx cancer: Clinical validation of intensity modulated radiotherapy experience and dosimetric significance. Head Neck. 2014 Dec 1. [Epub ahead of print]. PMID: 25445257
2. Morris ZS, Mohindra P, Kruser TJ. Combined chemo-radiation therapy in the treatment of squamous cell carcinoma of the head and neck; an evolving paradigm. Oncol Hematol Rev(US)., 2014;9:109-114.
3. Hoffman MR, McCulloch TM, Mohindra P, Das R, Geurts M, Harari PM. Simulation study of high-dose-rate brachytherapy for early glottic cancer.  Brachytherapy. 2016 Jan-Feb;15(1):94-101, PMID: 26614234
4. Barasch S, Mohindra P, Hennrick K, Hartig GK, Harari PM, Yang DT. Assessing p16 Status of Oropharyngeal Squamous Cell Carcinoma by Combined Assessment of the Number of Cells Stained and the Confluence of p16 Staining: A Validation by Clinical Outcomes. Am J Surg Pathol. 2016 Sep;40(9):1261-9, PMID: 27186851.

Contributions in Neuro-Oncology: 

1. Mohindra P, Sinha RN, Andrews RJ, Khuntia D. Non-cytotoxic radiosensitizers in brain radiotherapy: Journey till the first decade of this millennium. Curr Cancer Drug Targets., 2012;12:260-278. PMID: 22268387.
2. Mohindra P, Robins HI, Tomé WA, Hayes L, Howard S. Wide-field pulsed-reduced-dose-rate radiotherapy (PRDR) for recurrent ependymoma in pediatric and young adult patients. Anticancer Res., 2013;33:2611-2618. PMID: 23749916
3. Magnuson W, Robins HI, Mohindra P, Howard S. Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab. J Neurooncol., 2014;117:133-139. PMID: 24469853
4. Diwanji T, Snider JW, Lin JY, Engelman A, Mohindra P, Kwok Y., Mehta MP. Volumetric Analysis of the Hippocampus in Long Term (∼1 year) Survivors of Whole Brain-Radiation Therapy for Brain Metastasis. Int J Radiat Oncol Biol Phys. 2015;93(3):Supp 1, E69.  Abstract only.
5. Koroulakis A, Diwanji T, Lin J, Mohindra P, Mehta M. Subcortical Volumetric Changes in Patients Receiving Whole-Brain Radiation Therapy for Brain Metastases. American College of Radiation Oncology (ACRO) Annual Meeting, In: Orlando, FL; 2016. Abstract only.
6. Diwanji T, Snider JW, Koroulakis A, Feigenberg SJ, Mohindra P, Kwok Y., Mehta MP. Interobserver Variability in Atlas-Based, Manual Segmentation of the Hippocampus in Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2016;96(2):Supp 1, E130. Abstract only.
7. Diwanji TP, Engelman A, Snider JW, Mohindra P. Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther 2017 Sep,8:99-113

Contributions towards education in radiation oncology: Dr. Mohindra was involved in publication of the first ever report that described the factors assessed by MS4s during the process of radiation oncoloy residency selection. As one of the founding members of the education sub-committee of the Association of Residents in Radiation Oncology (ARRO), he was involved in a unique study assessing the factors involved in the job search and career planning both from the perspective of graduating residents and the hiring physicians. He developed multiple peer-reviewed educational presentations for the online educational resource through the ARRO. Further, he served as the institutional co-investigator for a multi-institutional introductory structured didactic radiation oncology curriculum for medical students pursuing a career in radiation oncology. These efforts have led to multiple publications.

1. Brower J, Mohindra P, Golden D, Bradley K. Radiation oncology residency selection: A targeted assessment of factor importance among fourth year medical students. Int J Radiat Oncol Biol Phys., 2014;88:967-968. PMID: 24606856
2. Ye JC, Mohindra P, Spektor A, Krishnan MS, Chmura SJ, Howard AR, Viswanathan AN, MacDonald SM, Thaker NG, Das P, Mancini BR, Higgins SA, Braunstein S, Haas-Kogan D, Bradley KA, Hung AY, Thomas CR Jr, Kharofa J, Wheatley M, Currey A, Parashar B, Du K, Jimenez RB, Golden DW. Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):217-9, PMID: 25968822
3. Nabavizadeh N, Burt LM, Mancini BR, Morris ZS, Walker AJ, Miller SM, Bhavsar S, Mohindra P, Kim MB, Kharofa J; ARRO Executive Committee. Results of the 2013-2015 Association of Residents in Radiation Oncology Survey of Chief Residents in the United States. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):228-34. Epub 2015 Oct 22.PMID: 26853332
4. Oskvarek JJ, Brower JV, Mohindra P, Raleigh DR, Chmura SJ, Golden DW. Educational Impact of a Structured Radiation Oncology Clerkship Curriculum: An Interinstitutional Comparison. J Am Coll Radiol. 2017 Jan;14(1):96-102, PMID: 27652570
5. Pranshu Mohindra, Steven P. Howard. ARROContour- Glioblastoma multiforme. Assoiation of Residents in Radiation Oncology (ARRO) Educational Resource.   https://www.astro.org/ARRO/Resident-Resources/Educational-Resources/ARROCase/index.aspx